PE20081780A1 - Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo - Google Patents

Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo

Info

Publication number
PE20081780A1
PE20081780A1 PE2007001607A PE2007001607A PE20081780A1 PE 20081780 A1 PE20081780 A1 PE 20081780A1 PE 2007001607 A PE2007001607 A PE 2007001607A PE 2007001607 A PE2007001607 A PE 2007001607A PE 20081780 A1 PE20081780 A1 PE 20081780A1
Authority
PE
Peru
Prior art keywords
quinolin
methyl
propionitrile
imidazo
dihydro
Prior art date
Application number
PE2007001607A
Other languages
English (en)
Inventor
Frank Stowasser
Markus Banziger
Sudhakar Devidasrao Garad
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081780A1 publication Critical patent/PE20081780A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

REFERIDA A UNA FORMA CRISTALINA A, B, C O D DEL 2-METIL-2-[4-(3-METIL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-1-IL)-FENIL]-PROPIONITRILO DE FORMULA (I). LA FORMA CRISTALINA A PRESENTA UN PICO EN LA DIFRACCION DE RAYOS-X DE 8,4 +/- 0,3 EN UN ANGULO DE DIFRACCION 2 THETA, LA FORMA CRISTALINA C PRESENTA UN PICO DE 14,7 +/- 0,3. DICHO COMPUESTO TIENE ACTIVIDAD INHIBIDORA DE LAS CINASAS DE LIPIDO, PARTICULARMENTE, LA CINASA-PI3
PE2007001607A 2006-11-20 2007-11-19 Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo PE20081780A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648306P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
PE20081780A1 true PE20081780A1 (es) 2009-01-01

Family

ID=39345299

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001508A PE20120083A1 (es) 2006-11-20 2007-11-19 Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
PE2007001607A PE20081780A1 (es) 2006-11-20 2007-11-19 Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001508A PE20120083A1 (es) 2006-11-20 2007-11-19 Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a

Country Status (36)

Country Link
US (2) US8436177B2 (es)
EP (2) EP2364981A1 (es)
JP (2) JP5562033B2 (es)
KR (3) KR20090080530A (es)
CN (5) CN109970735A (es)
AR (1) AR064256A1 (es)
AU (1) AU2007323820B2 (es)
BR (1) BRPI0719112A2 (es)
CA (1) CA2669199C (es)
CL (1) CL2007003316A1 (es)
CO (1) CO6382134A2 (es)
CR (1) CR10757A (es)
DO (1) DOP2009000116A (es)
EA (1) EA015677B1 (es)
EC (1) ECSP099340A (es)
GE (1) GEP20125436B (es)
GT (1) GT200900133A (es)
HK (1) HK1132739A1 (es)
HR (1) HRP20140627T1 (es)
IL (2) IL198467A (es)
JO (1) JO2903B1 (es)
MA (1) MA30967B1 (es)
MX (1) MX2009005360A (es)
MY (1) MY150216A (es)
NI (1) NI200900091A (es)
NO (1) NO20092227L (es)
NZ (1) NZ576357A (es)
PE (2) PE20120083A1 (es)
PH (1) PH12013502100A1 (es)
RS (1) RS53335B (es)
SM (1) SMP200900041B (es)
TN (1) TN2009000191A1 (es)
TW (2) TW201402567A (es)
UA (1) UA98473C2 (es)
UY (1) UY30728A1 (es)
WO (1) WO2008064093A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
BRPI0909082A2 (pt) * 2008-03-26 2019-02-26 Novartis Ag imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
EP2438064A1 (en) 2009-06-04 2012-04-11 Novartis AG 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
BR112012019459A2 (pt) 2010-02-03 2017-10-17 Signal Pharm Llc identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20140069038A (ko) * 2011-09-30 2014-06-09 다나-파버 캔서 인스티튜트 인크. 점액표피양 암종을 치료하는 방법
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG10201906270VA (en) 2013-03-21 2019-08-27 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
AU2014253978B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
CA2908830C (en) 2013-04-17 2021-12-07 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
JP6139789B2 (ja) 2013-10-16 2017-05-31 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合複素環化合物、その調製方法、医薬組成物及びその使用
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
BR112019010470A2 (pt) 2016-11-23 2019-09-10 Novartis Ag métodos de realce de resposta imune com everolimo, dactolisib ou ambos
BR112019027402A2 (pt) 2017-06-22 2020-07-07 Celgene Corporation tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN111187181B (zh) * 2019-11-22 2023-05-05 吉林大学 一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CN1902200A (zh) * 2003-11-21 2007-01-24 诺瓦提斯公司 用做蛋白激酶抑制剂的1h－咪唑并喹啉类衍生物
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2013173788A (ja) 2013-09-05
NI200900091A (es) 2010-02-17
WO2008064093A3 (en) 2008-08-14
TW201402567A (zh) 2014-01-16
SMP200900041B (it) 2009-09-07
NO20092227L (no) 2009-08-17
HRP20140627T1 (hr) 2014-09-26
PE20120083A1 (es) 2012-03-01
CO6382134A2 (es) 2012-02-15
PH12013502100A1 (en) 2015-09-21
JO2903B1 (en) 2015-09-15
SMAP200900041A (it) 2009-07-14
CR10757A (es) 2009-06-11
EP2094700B1 (en) 2014-04-02
RS53335B (en) 2014-10-31
CN101541793A (zh) 2009-09-23
EP2094700A2 (en) 2009-09-02
NZ576357A (en) 2011-01-28
MY150216A (en) 2013-12-13
CN109970735A (zh) 2019-07-05
GEP20125436B (en) 2012-03-26
AR064256A1 (es) 2009-03-25
CN106045993A (zh) 2016-10-26
CN102993202A (zh) 2013-03-27
TWI417292B (zh) 2013-12-01
CL2007003316A1 (es) 2008-06-27
IL198467A0 (en) 2010-02-17
BRPI0719112A2 (pt) 2013-12-10
WO2008064093A2 (en) 2008-05-29
JP2010510240A (ja) 2010-04-02
MX2009005360A (es) 2009-06-05
CA2669199A1 (en) 2008-05-29
IL198467A (en) 2014-11-30
HK1132739A1 (en) 2010-03-05
KR20090080530A (ko) 2009-07-24
KR20140129396A (ko) 2014-11-06
US20100168153A1 (en) 2010-07-01
TN2009000191A1 (en) 2010-10-18
ECSP099340A (es) 2009-06-30
UY30728A1 (es) 2008-07-03
EA200900638A1 (ru) 2009-12-30
MA30967B1 (fr) 2009-12-01
US20130289064A1 (en) 2013-10-31
US8436177B2 (en) 2013-05-07
UA98473C2 (ru) 2012-05-25
EA015677B1 (ru) 2011-10-31
CN102336752A (zh) 2012-02-01
IL219877A0 (en) 2012-06-28
GT200900133A (es) 2010-05-21
TW200827356A (en) 2008-07-01
JP5562033B2 (ja) 2014-07-30
AU2007323820B2 (en) 2012-02-23
EP2364981A1 (en) 2011-09-14
KR20140091718A (ko) 2014-07-22
DOP2009000116A (es) 2009-05-31
AU2007323820A1 (en) 2008-05-29
CA2669199C (en) 2015-12-29

Similar Documents

Publication Publication Date Title
PE20081780A1 (es) Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
SV2010003567A (es) Derivados bis-(sulfonilamino) en terapia 066
PA8791801A1 (es) Compuestos de pirazol
PA8821301A1 (es) Inhibidores a base de hidroxamato de desacetilasas b
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
CO6290687A2 (es) Inhibidores de cinasa pim y metodos para su uso
DOP2010000191A (es) Derivados bis-(sulfonilamino)
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
CR10088A (es) Compuestos de piperazina con accion herbicida
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
GT200500360A (es) Compuestos organicos
ES2546198T3 (es) Tratamiento contra la glomerulonefritis
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
UY32615A (es) Compuestos carboximida y su uso como inhibidores de calpaína
ECSP099565A (es) Compuesto de 2-amino pirimidina
UY32877A (es) Inhibidores heteroarílicos de cinasa.
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
ES2525528T3 (es) Amicolamicina, método para su producción y su utilización

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed